EP1231921A4 - Protease inhibitors - Google Patents

Protease inhibitors

Info

Publication number
EP1231921A4
EP1231921A4 EP00977065A EP00977065A EP1231921A4 EP 1231921 A4 EP1231921 A4 EP 1231921A4 EP 00977065 A EP00977065 A EP 00977065A EP 00977065 A EP00977065 A EP 00977065A EP 1231921 A4 EP1231921 A4 EP 1231921A4
Authority
EP
European Patent Office
Prior art keywords
protease inhibitors
protease
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00977065A
Other languages
German (de)
French (fr)
Other versions
EP1231921A1 (en
Inventor
Robert W Marquis Jr
Yu Ru
Daniel Frank Veber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1231921A1 publication Critical patent/EP1231921A1/en
Publication of EP1231921A4 publication Critical patent/EP1231921A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
EP00977065A 1999-11-10 2000-11-08 Protease inhibitors Withdrawn EP1231921A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16457699P 1999-11-10 1999-11-10
US164576P 1999-11-10
PCT/US2000/030703 WO2001034158A1 (en) 1999-11-10 2000-11-08 Protease inhibitors

Publications (2)

Publication Number Publication Date
EP1231921A1 EP1231921A1 (en) 2002-08-21
EP1231921A4 true EP1231921A4 (en) 2004-06-23

Family

ID=22595118

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00977065A Withdrawn EP1231921A4 (en) 1999-11-10 2000-11-08 Protease inhibitors

Country Status (3)

Country Link
EP (1) EP1231921A4 (en)
JP (1) JP2003513926A (en)
WO (1) WO2001034158A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
PL350132A1 (en) * 1998-12-23 2002-11-04 Smithkline Beecham Corp Protease inhibitors
EP1229914A4 (en) 1999-11-10 2004-06-23 Smithkline Beecham Corp Protease inhibitors
US6596715B1 (en) 1999-11-10 2003-07-22 Smithkline Beecham Corporation Protease inhibitors
EP1232154A4 (en) 1999-11-10 2004-06-23 Smithkline Beecham Corp Protease inhibitors
JP2003527429A (en) 2000-03-21 2003-09-16 スミスクライン・ビーチャム・コーポレイション Protease inhibitor
CO5280093A1 (en) * 2000-04-18 2003-05-30 Smithkline Beecham Corp TREATMENT METHODS
PL360508A1 (en) * 2000-06-14 2004-09-06 Smithkline Beecham Corporation Protease inhibitors
KR20220115062A (en) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 Pharmaceutical Composition For Treating and Preventing Osteoporosis Comprising Compounds of Chromone Scaffold

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038687A1 (en) * 1998-12-23 2000-07-06 Smithkline Beecham Corporation Protease inhibitors
WO2001095911A1 (en) * 2000-06-14 2001-12-20 Smithkline Beecham Corporation Protease inhibitors
WO2002017924A1 (en) * 2000-09-01 2002-03-07 Smithkline Beecham Corporation Method of treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038687A1 (en) * 1998-12-23 2000-07-06 Smithkline Beecham Corporation Protease inhibitors
WO2001095911A1 (en) * 2000-06-14 2001-12-20 Smithkline Beecham Corporation Protease inhibitors
WO2002017924A1 (en) * 2000-09-01 2002-03-07 Smithkline Beecham Corporation Method of treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0134158A1 *

Also Published As

Publication number Publication date
EP1231921A1 (en) 2002-08-21
WO2001034158A1 (en) 2001-05-17
JP2003513926A (en) 2003-04-15

Similar Documents

Publication Publication Date Title
PL349192A1 (en) Protease inhibitors
GB9912961D0 (en) Metalloprotease inhibitors
IL150964A0 (en) Protease inhibitors
EP1093367A4 (en) Protease inhibitors
IL145085A0 (en) Dihetero-substituted metalloprotease inhibitors
EP1067894A4 (en) Protease inhibitors
EP1235577A4 (en) Protease inhibitors
EP1079821A4 (en) Protease inhibitors
IL153421A0 (en) Protease inhibitors
EP1232155A4 (en) Protease inhibitors
EP1229914A4 (en) Protease inhibitors
EP1231921A4 (en) Protease inhibitors
EP1229912A4 (en) Protease inhibitors
EP1229915A4 (en) Protease inhibitors
HK1041690A1 (en) Protease inhibitors
EP1086083A4 (en) Protease inhibitors
IL151087A0 (en) Protease inhibitors
EP1351930A4 (en) Protease inhibitors
HK1044758A1 (en) Protease inhibitors
EP1229911A4 (en) Protease inhibitors
EP1161237A4 (en) Protease inhibitors
EP1233771A4 (en) Protease inhibitors
EP1231923A4 (en) Protease inhibitors
EP1231922A4 (en) Protease inhibitors
EP1232154A4 (en) Protease inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020603

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

A4 Supplementary search report drawn up and despatched

Effective date: 20040507

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 19/08 B

Ipc: 7A 61P 19/10 B

Ipc: 7C 07D 409/14 B

Ipc: 7A 61K 31/55 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060212